SEC Tracker
Get the app

PMV Pharmaceuticals PMVP

PMV Pharmaceuticals reported a net loss of $34.37 million

PMV Pharmaceuticals (PMVP) filed a 10-Q with the SEC on Nov 10, 2026, 8:02 am ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $34.37 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$0.52 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $19.99 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Going-concern warning repeated

“In connection with the issuance of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the "Q2 2026 10-Q"), management determined that the Company's then-available cash, cash equivalents, and marketable securities may not have been sufficient…”
In the notes to the financial statements. Read it in the filing 10-Q on EDGAR

Also in the prior 10-Q (filed Aug 14, 2026). Prior report Prior on EDGAR

Quoted from the filing.

Get an email when PMV Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$20.06M−$18.88M−6.3%
Net income−$34.37M−$18.09M−90%
Operating cash flow−$18.18M−$14.58M−25%
Cash$19.99M$12.47M+60%

Data on this page was fetched . The filing on SEC.gov is the record.